The British Journal of Clinical Pharmacology

Volume 54
2002

Published for
The British Pharmacological Society by
Blackwell Science

© 2002, Blackwell Publishing Ltd
Osney Mead, Oxford OX2 0EL
23 Ainslie Place, Edinburgh EH3 6AJ
Commerce Place, 350 Main Street, Malden MA 02148-5018, USA
54 University Street, Carlton, Victoria 3053, Australia

Other Editorial Offices:
Blackwell Wissenschafts-Verlag GmbH
Kurfürstendamm 57
1707 Berlin
Germany

Blackwell Science KK
MG Kodenmacho Building
7-10 Kodenmacho Nihombashi
Chuo-ku, Tokyo 104
Japan

Published on behalf of
The British Pharmacological Society

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the copyright owner. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Blackwell Science for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of $15.00 per copy is paid directly to CCC, 222 Rosewood Drive, Suite 910, Danvers, MA 01923, USA. 0206-5251/01 $15.00/0. (For copying beyond that permitted by Sections 107 or 108 of the US Copyright Law). This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Special requests should be addressed to the Editor.

Typeset by SNP Best-set Typesetter Ltd., Hong Kong
Printed and Bound by The Charlesworth Group, Huddersfield

Contents

This article is considered particularly suitable for continuing medical education.

Volume 54, Number 1, July 2002

For debate

1 Clinical Pharmacology: Principles and practice of drug therapy in medical education: *B. Whiting, N.H.G. Holford & E.J. Begg*

Special article

3 Web based information on clinical toxicology for the United Kingdom: uptake and utilization of TOXBASE in 2000: *D.N. Bateman, A.M. Good, C.A. Kelly & W.J. Laing*

Review

11 Serotonergic modulating drugs for functional gastrointestinal diseases: *R. Spiller*

Commentary

21 Nonlinear dynamics in Clinical Pharmacology: the paradigm of cortisol secretion and suppression: *A. Dokoumetzidis, A. Iliadis & P. Macheras*

Pharmacokinetics

31 Caffeine in apnoeic Asian neonates: a sparse data analysis: *H.S. Lee, Y.M. Khoo, Y. Chirino-Barcelo, K.L. Tan & D. Ong*

Pharmacodynamics

38 The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects: *P. Tfelt-Hansen, K. Seidelin, M. Stepanavage & C. Lines*

45 Prior iontophoresis of saline enhances vasoconstriction to phenylephrine and clonidine in the skin of the human forearm: *P.D. Drummond*

51 Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers: *J.M. Gandon & H. Allain*

Pharmacovigilance

59 Inhaled corticosteroids and the risk of diabetes among the elderly: *N. Dendukuri, L. Blais & J. LeLorier*

Short report

65 Sirolimus steady-state trough concentrations are not affected by bolus methylprednisolone therapy in renal allograft recipients: *L. Bäckman, H. Kreis, J.M. Morales, H. Wilczek, R. Taylor & J.T. Burke*

Letter to the Editors

69 CYP2D6 deficiency, a factor in ecstasy related deaths?: *T.C. Gilhooly & A.K. Daly*

Book review

71 The Desktop Guide to Complementary and Alternative Medicine: *B. Kirby*

3rd meeting on clinical measurement and new drug development

73 Editorial: 3rd meeting on clinical measurement and new drug development, Royal Society of Edinburgh, 13–14 June 2001: *W.S. Nimmo & G. Tucker*

75 Surrogacy in antiviral drug development: *S. Shaunak & D.S. Davies*

81 What should we measure in the diabetic patient and how does this respond to therapy?: *D.G. Johnston, S. Robinson & S. Forbes*

87 Measurement of renal function during drug development: *D.C. Brater*

96 Measurement of thrombosis and its prevention: *G.D.O. Lowe*

Volume 54, Number 2, August 2002

Pharmacokinetics

101 Pharmacokinetics of tibolone in early and late postmenopausal women: *C.J. Timmer, H.A.M. Verheul & D.P. Doorstam*

107 Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose: *B.C. Sallustio, I.S. Westley & R.G. Morris*

115 Determination of the relative bioavailability of salbutamol to the lungs and systemic circulation following nebulization: *V.L. Silkstone, S.A. Corlett & H. Chrystyn*

120 Intestinal first pass metabolism of midazolam in liver cirrhosis – effect of grapefruit juice: *V. Andersen, N. Pedersen, N.-E. Larsen, J. Sonne & S. Larsen*

125 Enantioselective distribution of albendazole metabolites in cerebrospinal fluid of patients with neurocysticercosis: *O.M. Takayanagui, P.S. Bonato, S.A.C. Dreossi & V.L. Lanchote*

131 Relationships between body composition parameters and fluorouracil pharmacokinetics: *M. Gusella, S. Toso, E. Ferrazzi, M. Ferrari & R. Padrini*

Pharmacokinetics/pharmacodynamics

140 An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria: *A. Mattheus, T.N. Johnson, A. Rostami-Hodjegan, A. Chakrapani, J.E. Wraith, S.J. Moat, J.R. Bonham & G.T. Tucker*

147 Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis: *J. Chládek, J. Grim, J. Martínková, M. Šimková, J. Vaníèková, V. Koudelková & M. Noièková*

Drug disposition

157 The influence of *CYP2B6*, *CYP2C9* and *CYP2D6* genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver: *J.K. Coller, N. Krebsfaenger, K. Klein, K. Endrizzi, R. Wolbold, T. Lang, A. Nüssler, P. Neuhaus, U.M. Zanger, M. Eichelbaum & T.E. Mürdter*

Therapeutics

168 Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa: *D.A.M.C. van de Vijver, R.A.C. Roos, P.A.F. Jansen, A.J. Porsius & A. de Boer*

Pharmacovigilance

171 Non-antiarrhythmic drugs prolonging the QT interval: considerable use in seven countries: *F. De Ponti, E. Poluzzi, A. Vaccheri, U. Bergman, L. Bjerrum, J. Ferguson, K.J. Frenz, P. McManus, I. Schubert, G. Selke, G. Tèrzis-Vaslamatzis & N. Montanaro*

Short report

178 Interaction between saquinavir soft-gel and rifabutin in patients infected with HIV: *G.J. Moyle, N.E. Buss, T. Goggin, P. Snell, C. Higgs & D.A. Hawkins*

Letter to the Editors

183 Intra-individual variability in urinary losartan oxidation ratio, an *in vivo* marker of CYP2C9 activity: *Ü. Yasar, M.-L. Dahl, M. Christensen & E. Eliasson*

Book reviews

186 Drug benefits and risks: International Textbook of Clinical Pharmacology: *F. Bochner*

187 Complementary therapies for pharmacists: *T.N. Johnson*

3rd meeting on clinical measurement and new drug development

188 The significance of QT interval in drug development: *R.R. Shah*

203 Is intent-to-treat analysis always (ever) enough?: *L.B. Sheiner*

212 The odds of the three nons when an aptly prescribed medicine isn't working non-compliance, non-absorption, non-response: *J. Urquhart*

221 Pharmacogenetics and the future of medical practice: *K. Lindpaintner*

Volume 54, Number 3, September 2002

GLAXOSMITHKLINE PRIZE 2000

231 Antagonism of long-acting β_2-adrenoceptor agonism: *B.J. Lipworth*

Pharmacokinetics

246 Stereoselective urinary excretion of formoterol and its glucuronide conjugate in human: *M. Zhang, J.P. Fawcett & J.P. Shaw*

251 Quinidine does not affect the renal clearance of moxonidine: *S.D. Wise, C. Chan, H.G. Schaefer, M.M. He, I.J. Pouliquen & M.I. Mitchell*

255 Pharmacokinetics and gamma scintigraphy evaluation of two enteric coated formulations of didanosine in healthy volunteers: *B. Damle, I. Ullah, W. Doll, G. Wiley & C. Knupp*

262 The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects: *M. Boffito, P.G. Hoggard, H.E. Reynolds, S. Bonora, E.R. Meaden, A. Sinicco, G.D. Perri & D.J. Back*

Pharmacodynamics

269 Early clinical experience with the novel proteasome inhibitor PS–519: *I.M. Shah, K.R. Lees, C.P. Pien & P.J. Elliott*

277 The effects of St John's wort extract on heart rate variability, cognitive function and quantitative EEG: a comparison with amitriptyline and placebo in healthy men: *M. Siepmann, S. Krause, P. Joraschky, M. Mück-Weymann & W. Kirch*

Pharmacokinetics/pharmacodynamics

283 Pharmacokinetics and pharmacodynamics of TF-505, a novel nonsteroidal 5α-reductase inhibitor, in normal subjects treated with single or multiple doses: *T. Fujita, Y. Matsumoto, T. Kimura, S. Yokota, M. Sawada, M. Majima, Y. Ohtani & Y. Kumagai*

Drug disposition

295 Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential: *S. Furuta, N. Akagawa, E. Kamada, A. Hiyama, Y. Kawabata, N. Kowata, A. Inaba, A. Matthews, M. Hall & T. Kurimoto*

Drugs interactions

304 Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin: *R.A. Faaij, J. Burggraaf, R.C. Schoemaker, R.G.M. van Amsterdam & A.F. Cohen*

309 Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin *T. Kosoglou, I. Meyer, E.P. Veltri, P. Statkevich, B. Yang, Y. Zhu, L. Mellars, S.E. Maxwell, J.E. Patrick, D.L. Cutler, V.K. Batra & M.B. Affrime*

Therapeutics

320 Dose–response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data: *S.C. Lewis, M.J.S. Langman, J.-R. Laporte, J.N.S. Matthews, M.D. Rawlins & B.-E. Wiholm*

327 Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction: *R.G. Schlienger, H. Jick & C.R. Meier*

Letters to the Editors

333 Double injection *vs* skin microdialysis technique in minimally invasive *in vivo* pharmacology: *P.K. Rao, P.E. Pérgola, N.M. Habiba, Y. Liu & D.L. Kellogg*

334 Cyclosporin enhances the tendency towards oedema and flushing noted on dihydropyridine calcium channel blockers: *R.O. von Vigier, E. Fossali, A. Edefonti, B. Vogt & M.G. Bianchetti*

335 Spontaneous reporting of adverse drug reactions in Cuba: integrating continuous education, training and research in a network approach: *F. Debesa, G. Jiménez, A. Figueras, E. Diogène, J.P. Peña, J. Avila & J.-R. Laporte*

Book reviews

337 ACE inhibitors: *N.F. Kelland & D.J. Webb*

338 Introduction to proteomics: *S. Murray*

Volume 54, Number 4, October 2002

Editorial

341 A spoonful of sugar? *Tomorrow's Doctors 2002: D.J. Webb & S.R.J. Maxwell*

Review series

Review Series on Pharmacogenetics edited by Prof. M. Pirmohamed

344 Receptor pharmacogenetics: relevance to CNS syndromes: *S. Shaikh & R.W. Kerwin*

Review

349 St John's wort (*Hypericum perforatum*): drug interactions and clinical outcomes: *L. Henderson, Q.Y. Yue, C. Bergquist, B. Gerden & P. Arlett*

Pharmacokinetics

357 Absolute bioavailability of midazolam after subcutaneous administration to healthy volunteers: *M. Pecking, F. Montestruc, P. Marquet, E. Wodey, M.-C. Homery & P. Dostert*

363 Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose: *H. Heikkinen, A. Varhe, T. Laine, J. Puttonen, M. Kela, S. Kaakkola & K. Reinikainen*

372 Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids: *P. Snell, C. Oo, A. Dorr & J. Barrett*

378 Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals: *M.M.R. de Maat, A.D.R. Huitema, J.W. Mulder, P.L. Meenhorst, E.C.M. van Gorp & J.H. Beijnen*

Pharmacodynamics

386 Repeatability of local forearm vasoconstriction to endothelin-1 measured by venous occlusion plethysmography: *F.E. Strachan, D.E. Newby, D.G. Sciberras, J.B. McCrea, M.R. Goldberg & D.J. Webb*

395 Direct *in vivo* evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects: *H. Omori, H. Nagashima, Y. Tsurumi, A. Takagi, N. Ishizuka, N. Hagiwara, M. Kawana & H. Kasanuki*

400 Central and peripheral effects of sustained caffeine use: tolerance is incomplete: *J. Watson, I. Deary & D. Kerr*

Pharmacokinetics/pharmacodynamics

407 Correlation and predictive performances of saliva and plasma nicotine concentration on tobacco withdrawal-induced craving: *V. Teneggi, L. Squassante, L. Iavarone, S. Milleri, A. Bye & R. Gomeni*

415 Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery: *C.A.J. Knibbe, G. Melenhorst-de Jong, M. Mestrom, C.M.A. Rademaker, A.F.A. Reijnvaan, K.P. Zuideveld, P.F.M. Kuks, H. van Vught & M. Danhof*

Drug disposition

423 Oxidation of celecoxib by polymorphic cytochrome P450 2C9 and alcohol dehydrogenase: *M. Sandberg, Ü. Yasar, P. Strömberg, J.-O. Höög & E. Eliasson*

Clinical toxicology

430 Paracetamol-related deaths in Scotland, 1994–2000: *C.L. Sheen, J.F. Dillon, D.N. Bateman, K.J. Simpson & T.M. MacDonald*

Pharmacovigilance

433 Perception of the risk of adverse drug reactions: differences between health professionals and non health professionals: *V. Bongard, S. Ménard-Taché, H. Bagheri, K. Kabiri, M. Lapeyre-Mestre & J.L. Montastruc*

Drug prescribing

437 The pharmacological treatment of schizophrenia in Chinese patients: a comparison of prescription patterns between 1996 and 1999: *G.S. Ungvari, Y.G. Chung, Y.K. Chee, N. Fung-Shing, T.W. Kwong & H.F.K. Chiu*

Short report

445 *In vitro* permeation of β-lactam antibiotics across rat jejunum and its correlation with oral bioavailability in humans: *H. Saitoh, B.J. Aungst, M. Tohyama, Y. Hatakeyama, K. Ohwada, M. Kobayashi, H. Fujisaki & K. Miyazaki*

Volume 54, Number 5, November 2002

Pharmacokinetics

449 Effect of severe renal impairment on the pharmacokinetics of azimilide following single dose oral administration: *A.E. Corey, J.R. Agnew, S.N. Valentine, N.J. Parekh, J.H. Powell & G.A. Thompson*

453 Pharmacokinetics and safety of JTE-522, a novel selective cyclooxygenase-2 inhibitor, in healthy male volunteers: *Y. Ikeda, K. Umemura, K. Kondo, M. Nakashima, T. Kobayashi & M. Takahashi*

463 Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide): *C. van Kesteren, R.A.A. Mathôt, E. Raymond, J.P. Armand, P. Fumoleau, C. Punt, M. Ravic, J. Wanders, J.H. Beijnen, J.H.M. Schellens on behalf of the Early Clinical Studies Group of the EORTC and NDDO Oncology*

Pharmacokinetics/pharmacodynamics

472 Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers: *P.D. Martin, P.D. Mitchell & D.W. Schneck*

478 Pharmacokinetic and pharmacodynamic profile following oral administration of the phosphodiesterase (PDE)4 inhibitor V11294A in healthy volunteers: *D.D. Gale, L.J. Landells, D. Spina, A.J. Miller, K. Smith, T. Nichols, Y. Rotshteyn, A. Tonelli, P. Lacouture, R.M. Burch, C.P. Page & B.J. O'Connor*

485 Pharmacokinetics and electrocardiographic pharmacodynamics of artemether-lumefantrine (Riamet®) with concomitant administration of ketoconazole in healthy subjects: *G. Lefèvre, P. Carpenter, C. Souppart, H. Schmidli, M. McClean & D. Stypinski*

Drug metabolism

493 *In vitro–in vivo* correlations for drugs eliminated by glucuronidation: Investigations with the model substrate zidovudine: *S. Boase & J.O. Miners*

504 The effect of the *CYP1A2 *1F* mutation on CYP1A2 inducibility in pregnant women: *A. Nordmark, S. Lundgren, B. Ask, E. Granath & A. Rane*

511 Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism: *R. Yoshida, M. Nakajima, Y. Watanabe, J.-T. Kwon & T. Yokoi*

518 Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population: *M. Burian, S. Grösch, I. Tegeder & G. Geisslinger*

Pharmacovigilance

522 A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practice: *C. Cutts, A. LaCaze & S. Tett*

Short reports

528 Drug reimbursement: Indicators of inappropriate resource allocation: *B. Bégaud, U. Bergman, H.-G. Eichler, H.G.M. Leufkens & P.J. Meier*

535 Spatial distribution of 8-methoxypsoralen penetration into human skin after systemic or topical administration: *M. Grundmann-Kollmann, M. Podda, L. Bräutigam, K. Hardt-Weinelt, R.J. Ludwig, G. Geisslinger, R. Kaufmann & I. Tegeder*

540 Inducibility of CYP1A2 by omeprazole *in vivo* related to the genetic polymorphism of *CYP1A2*: *X.-M. Han, D.-S. Ouyang, X.-P. Chen, Y. Shu, C.-H. Jiang, Z.-R. Tan & H.-H. Zhou*

544 Effect of plastic spacer handling on salbutamol lung deposition in asthmatic children: *B.J. Lipworth, D.K.C. Lee, J. Anhøj & H. Bisgaard*

Letters to the Editors

548 Prevalence of factitious hypoglycaemia associated with sulphonylurea drugs in France in the year 2000: *T. Trenque, C. Frances, H. Millart, G. Hoizey & M.L. Germain*

548 Penetration of fosfomycin into the parenchyma of human brain: a case study in three patients: *M. Brunner, A. Reinprecht, U. Illievich, C.K. Spiss, P. Dittrich, M. van Houte & M. Müller*

550 Does age increase the risk of adverse drug reactions?: *B. Bégaud, K. Martin, A. Fourrier & F. Haramburu*

553 Proceedings of the Dutch Society for Clinical Pharmacology and Biopharmacy, 19 April 2002

Volume 54, Number 6, December 2002

Review Series on Research Methods in Human Cardiovascular Pharmacology edited by Dr S. Maxwell and Prof. D. Webb

565 Assessment of venous capacitance. Radionuclide plethysmography: methodology and research applications: *M. Schmitt, D.J. Blackman, G.W. Middleton, J.R. Cockcroft & M.P. Frenneaux*

Review

577 A systematic review of systematic reviews of homeopathy: *E. Ernst*

Pharmacokinetics

583 The pharmacokinetics of ketobemidone in critically ill patients: *A. Al-Shurbaji & L. Tokics*

587 Faster absorption of ethanol and higher peak concentration in women after gastric bypass surgery: *H. Klockhoff, I. Näslund & A.W. Jones*

592 Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine: *I. Meineke, S. Freudenthaler, U. Hofmann, E. Schaeffeler, G. Mikus, M. Schwab, H.W. Prange, C.H. Gleiter & J. Brockmöller*

604 Quinine pharmacokinetics in chronic haemodialysis patients: *L. Roy, M. Leblanc, P. Bannon & J.-P. Villeneuve*

610 MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males: *T. Gerloff, M. Schaefer, A. Johne, K. Oselin, C. Meisel, I. Cascorbi & I. Roots*

Pharmacodynamics

617 No effect on central or peripheral blood pressure of systemic urotensin II infusion in man: *J.T. Affolter, D.E. Newby, I.B. Wilkinson, M.J. Winter, R.J. Balment & D.J. Webb*

622 Effect of candesartan, a type 1 angiotensin II receptor antagonist, on bronchial hyper-responsiveness to methacholine in patients with bronchial asthma: *S. Myou, M. Fujimura, Y. Kamio, T. Kita, K. Watanabe, Y. Ishiura, T. Hashimoto & S. Nakao*

627 Quantification of heparin-induced TFPI release: a maximum release at low heparin dose: *M.J.B. Kemme, J. Burggraaf, R.C. Schoemaker, C. Kluft & A.F. Cohen*

Pharmacokinetics/pharmacodynamics

635 Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration: *B.R. Ogutu, C.R.J.C. Newton, S.N. Muchohi, G.O. Otieno & G.O. Kokwaro*

Drug disposition

643 Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?: *S. Wanwimolruk, M.F. Paine, S.N. Pusek & P.B. Watkins*

Therapeutics

652 Amoxicillin/clavulanic acid is ineffective at preventing otitis media in children with presumed viral upper respiratory infection: a randomized, double-blind equivalence, placebo-controlled trial: *E. Autret-Leca, B. Giraudeau, M.J. Ployet & A.-P. Jonville-Béra*

657 The value of inpatient pharmaceutical counselling to elderly patients prior to discharge: *S.A. Al-Rashed, D.J. Wright, N. Roebuck, W. Sunter & H. Chrystyn*

665 Adverse drug reactions and off-label drug use in paediatric outpatients: *B. Horen, J.-L. Montastruc & M. Lapeyre-Mestre*

Short reports

671 Association between the N-acetylation genetic polymorphism and bronchial asthma: *M. Nacak, A.S. Aynacioglu, A. Filiz, I. Cascorbi, M.E. Erdal, N. Yilmaz, E. Ekinci & I. Roots*

675 Renal ^{131}I-hippuran extraction in man: effects of dopamine: *M. Hutchings, B. Hesse, J. Gronvall & N.V. Olsen*

Letters to the Editors

678 Limited adherence to safety instructions in drug leaflets: *H.J. Derijks, G.H.P. de Koning, A.K. Mantel-Teeuwisse & A.C.G. Egberts*

679 The effect of diltiazem, a calcium channel blocker, in asthmatic patients: *F. Quintieri, A. D'Ambrosio & A. Bachetoni*

680 Serotonergic modulating drugs for functional GI disease: the complex pharmacology of serotonergic drugs: *F. De Ponti & F. Crema*

681 Serotonergic modulating drugs for functional GI disease: the complex pharmacology of serotonergic drugs. Reply from author: *R. Spiller*

682 Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval: *M. Malik*

Book review

684 Nurse Prescribing, 2nd edition: *N. Baber*

687 Indices for Volume 54